Regenxbio (FRA:RB0) Valuation Rank


FRA:RB0 Regenxbio Inc FRA:RB0
55 GF Score
Price €13.00
GF Value €12.61
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Regenxbio Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Regenxbio Valuation Rank Related Terms

FRA:RB0
55GF Score
Regenxbio Inc FRA:RB0
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Regenxbio (FRA:RB0) Overvalued in 2026?

Based on GuruFocus' analysis, Regenxbio stock appears to be overvalued. The current stock price of €13.00 is trading 3.1% above its estimated GF Value™ of €12.61. GuruFocus considers Regenxbio to be Fairly Valued.

Key valuation signals for FRA:RB0:

  • Valuation Rank:
  • GF Value™: €12.61 vs. price of €13.00 (3.1% above fair value)
  • GF Score™: 55/100 with 9 warning signs

No single metric tells the full story. See the FRA:RB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regenxbio Business Description

Other Exchanges RGNX:USARB0:Germany
Address 9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
55GF Score

Get the complete analysis for FRA:RB0

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.00
Price
€12.61
GF Value